To include your compound in the COVID-19 Resource Center, submit it here.

ExCellThera’s safer allogeneic transplants

How ExCellThera is increasing the safety of allogeneic stem cell transplants

ExCellThera Inc. is expanding cord blood into allogeneic stem cell transplants for cancer that have lower treatment-related mortality rates and GvHD incidence than competing technologies.

Hematopoietic stem cell transplants (HSCTs) of unexpanded cord blood have two key drawbacks, according to CFO and Chief Legal Officer David Millette. First, only about 5% of cord blood samples contain enough stem cells to treat an adult, restricting their use. Second, despite

Read the full 678 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers